RADIOPHARMACEUTICALS: DIAGNOSIS AND TREATMENT OF CANCER

放射性药物可以诊断和治疗癌症。 近期 单克隆抗体的发展迅速， 针对个体癌症的治疗大大拓宽了人们的视野 放射性药物。 然而我们才刚刚开始探索 放射性药物的临床应用 的一个主要原因 放射性标记的化合物仅缓慢地达到临床应用， 它们的发展有多个连续的步骤， 每一步都需要专业科学家的专业知识。 这 这一过程成本高昂，难以协调。 很少有学术 组织拥有广泛的专业知识， 企业和制药公司可能会看到，但有限的 市场的单一放射性药物针对特定的 癌 事实上，这样的放射性药物成为“孤儿 药物”，具有巨大临床价值但过于昂贵而无法吸引 “父母” 我们提出了一个方案项目，将使 有序开发有用的放射性标记化合物， 概念和生产通过临床试验在诊断和 治疗癌症。 该计划项目将把科学家组织成核心， 合作将确保一个有前途的代理人将有效地 从合成到放射性药物再到临床 评价 该项目将支持一个 放射性药物开发核心设施包括：1） 生产和标签; 2）临床前评价; 3）剂量测定; 4)临床评价; 5）行政核心。 每个核心将 由有足够时间和知识的科学家组成， 进行专门而协调的实验，每个核心将 有足够的空间、设备和资金支持 这些科学家。 他们的努力将由校长协调 以确保疗效 在项目资助中。 联合国系统支助的跨学科协同次级项目 设施包括评价放射性药物开发 从：单克隆抗体的诊断和可能的 治疗：淋巴瘤、膀胱癌和乳腺癌以及 去甲肾上腺素类似物间碘苄胍诊断 治疗神经母细胞瘤 这些放射性药物 在动物中更好地评估，通过发展一个高- 分辨率小动物断层成像装置。 通过这个 核心实验室支持的一系列相互加强的项目， 最终结果应该是改善诊断和治疗 癌

Radiopharmaceuticals can diagnose and treat cancer. The recent explosion in development of monoclonal antibodies specifically directed at individual cancers has greatly broadened the horizons of radiopharmaceuticals. Yet we have only begun to explore these clinical uses of radiopharmaceuticals. A major reason that radiolabeled compounds have only slowly reached clinical utility is that there are multiple sequential steps in their development with each step requiring the expertise of specialized scientists. This process is expensive and difficult to coordinate. Few academic organizations have the broad-ranging expertise to undertake such ventures, and pharmaceutical companies may see but a limited market for a single radiopharmaceutical directed at a particular cancer. Indeed, such radiopharmaceuticals become "orphan drugs", agents of great clinical value but too costly to attract a "parent". We propose a program project that will enable the orderly development of useful radiolabeled compounds from concept and production through clinical trials in the diagnosis and treatment of cancers. The program project will organize scientists into cores where collaberations will ensure that a promising agent will efficiently proceed from synthesis to radiopharmaceutical to clinical evaluation. The program project will support a radiopharmaceutical development core facility composed of 1) production and labeling; 2) pre-clinical evaluation; 3) dosimetry; 4) clinical evaluation; and 5) administrative cores. Each core will consist of scientists with sufficient time and knowledge to carry out specialized yet coordinated experiments, and each core will have the space, equipment and funds to support the efforts of these scientists. Their efforts will be coordinated by the principal investigator and an administrative committee to ensure efficacy in the program project grant. Interdisciplinary, synergistic sub-projects supported by the facility include the evaluation of radiopharmaceuticals developed from: monoclonal antibodies for the diagnosis and possible therapy of: lymphoma, bladder and breast cancers as well as metaiodobenzylguanidine an analog of norepinephrine to diagnose and treat neuroblastomas. These radiopharmaceuticals will be better evaluated in animals through the development of a high- resolution small animal tomographic imaging device. Through this series of mutually reinforcing projects supported by the core labs, the end result should be improved diagnosis and treatment of cancer.